Clinical trials: Pseudomonas Infections
Bloodstream Infection
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P.
- Trial name
- SHORTEN2 (NCT05210439)
- Testing
- Short-treatment of any active antibiotic regimen, Long-treatment of any active antibiotic regimen
- Where
- 37 sites in Spain
- Volunteers
- 306 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Ventilation Acquired Pneumonia
Management of Ventilation Acquired Pneumonia Caused by Pseudomonas and Acinetobacter Organisms in a Pediatric Center
The goal of this clinical trial is to determine the most effective empirical therapy of antibiotics for better ventilator-associated pneumonia control.
- Trial name
- NCT06739382
- Testing
- extended meropenem infusion in combination with other options such as Polymyxin, Tigecycline, Ertapenem, or Amikacin., two β-lactam antibiotics plus a single non-β-lactam antibiotic, Control group received standard therapy
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Beni-Suef University
Cystic Fibrosis, Pulmonary Disease, Chronic Obstructive
Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic fibrosis (CF) is a chronic disease that significantly affects an individual's lung function. Antibiotic medications have been proven effective at reducing Pseudomonas aeruginosa (PA) infection, which is one of the main…
- Trial name
- EPIC (NCT00097773)
- Testing
- Tobramycin solution for inhalation (TOBI), Oral ciprofloxacin
- Where
- 54 sites in United States
- Volunteers
- 304 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis
Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection
The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa.
- Trial name
- NCT01316276
- Testing
- Liposomal amikacin for inhalation
- Where
- 50 sites in Austria, Belgium and 15 more
- Volunteers
- 206 people
- Sponsor
- Insmed Incorporated
Joint Infection
Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa
This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip.
- Trial name
- NCT06798168
- Testing
- Combining bacteriophage therapy with antibiotics for a case with hip PJI
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Cystic Fibrosis
Detection of Pseudomonas Aeruginosa in the Airways of Patients With CF
The purpose of this study is to determine if inhaled urea can be used to detect the presence of Pseudomonas Aeruginosa in the lungs
- Trial name
- NCT01303068
- Testing
- 13C urea breath test Kit
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Pseudomonas Aeruginosa Infection
Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals
Isolation and identification of Pseudomonas aeruginosa using basic microbiological methods, such as Gram staining, cultivation on cetrimide agar and biochemical reactions from Samples from patients with different types of health…
- Trial name
- NCT06417593
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Bronchiectasis Adult, Pseudomonas Aeruginosa Infection
Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis
People with bronchiectasis are prone to Pseudomonas aeruginosa (PA) infections, which can become chronic and lead to increased death rates and disease severity.
- Trial name
- ERASE (NCT06093191)
- Testing
- Tobramycin Inhalant Product, Ciprofloxacin 750 MG, Natural saline inhalation
- Where
- 60 sites in China
- Volunteers
- 371 people
- Sponsor
- Jin-Fu Xu
Trauma, Resistant Infection
Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
The purpose of this study is to assess the safety and efficacy of polymyxin B as monotherapy versus a combined polymyxin B-carbapenem therapy against multidrug-resistant (MDR) gram negative infections.
- Conditions
- Trauma, Resistant Infection, Critical Illness
- Trial name
- MUSEUM (NCT03159078)
- Testing
- Polymyxin B
- Where
- Puerto Rico
- Volunteers
- 40 people
- Sponsor
- University of Puerto Rico
Cystic Fibrosis, Lung Disease
Benefits and Risks of Newborn Screening for Cystic Fibrosis
Although cystic fibrosis (CF) is the most common, life-threatening autosomal recessive genetic disorder of the white population, there are often delays in diagnosis and hence start of treatment.
- Conditions
- Cystic Fibrosis, Lung Disease, Pseudomonas Infections
- Trial name
- NCT00014950
- Testing
- CF newborn screening
- Where
- 2 sites in United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and…
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
- Trial name
- NCT07708116
- Testing
- CTX-187
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centauri Therapeutics Limited
Infection Resistant to Drugs, Gram-Negative Bacterial Infection
Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals
This study aims to assess how large an additional disease burden and what extra costs are generated by antibiotic resistance in patients suffering from infections caused by gram-negative bacteria, such as Escherichia coli and…
- Trial name
- GRAND-ABC (NCT02007343)
- Where
- 8 sites in Netherlands
- Volunteers
- 3,895 people
- Sponsor
- UMC Utrecht
Pseudomonas Aeruginosa, Ventilation Acquired Pneumonia
Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)
Pseudomonas aeruginosa is the main pathogen of nosocomial respiratory infections. Its increasing resistance to antibiotics requires the development of new strategies for prevention and control, demanding a better understanding of…
- Trial name
- PYO GEN (NCT01745796)
- Where
- France
- Volunteers
- 77 people
- Sponsor
- University Hospital, Grenoble
Non-Small Cell Lung Cancer, Adenocarcinoma
A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma
Background: Advanced cases of non-small-cell lung carcinoma (NSCLC) usually are not successfully treated with standard therapies. Even treatments that attempt to specifically target NSCLC cells have not proved effective.
- Trial name
- NCT01051934
- Testing
- SS1 (dsFv) PE38, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Pseudomonas Aeruginosa, Ventilator Associated Pneumonia
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen that rarely causes disease in healthy people, but is a significant problem for critically ill or immunocompromised individuals.
- Trial name
- NCT00691587
- Testing
- KB001
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Humanigen, Inc.
Bronchiectasis With Pseudomonas Aeruginosa Colonization
A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
- Trial name
- BREEZE (NCT07774403)
- Testing
- AZD0292
- Where
- 40 sites in China
- Volunteers
- 84 people
- Sponsor
- AstraZeneca
Osteomyelitis, Pseudomonas Infections
Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa
This study looks at how well one antibiotic (monotherapy) works compared to two antibiotics (combination therapy) in treating bone infections caused by Pseudomonas aeruginosa.
- Conditions
- Osteomyelitis, Pseudomonas Infections, Pseudomonas Aeruginosa, Bacterial Infections
- Trial name
- NCT07056881
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Cystic Fibrosis, Infection
Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis
Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will prevent infections with this bacteria in patients with Cystic fibrosis (CF).
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- PseudIgY (NCT00633191)
- Testing
- Anti-pseudomonas IgY gargle
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Immunsystem AB
Bronchiectasis
Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa
It is acknowledged that IL-18, as a product of the inflammasome, is involved in host defence against viral and bacterial stimuli by modulating the immune response.
- Trial name
- NCT02491723
- Testing
- Azithromycin
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jin-Fu Xu